Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells

Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells

Abstract Objectives Bispecific antibodies targeting CD47 and PD‐L1 (CD47 × PD‐L1 BisAb) demonstrate efficacy against a range of solid cancers. While dual blockade negates anti‐CD47‐mediated toxicity, the effect of combined innate and adaptive immune activation on protective tumor‐resident CD8+ T cel...

Full description

Saved in:

Bibliographic Details
Main Authors:	Susan N Christo, Keely M McDonald, Thomas N Burn, Nadia Kurd, Jessica Stanfield, Megan M Kaneda, Ruth Seelige, Christopher P Dillon, Timothy S Fisher, Bas Baaten, Laura K Mackay
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Clinical & Translational Immunology
Subjects:	adaptive immunity CD47 CD8+ T cells immune checkpoint blockade immunotherapy tumor‐resident CD8+ T cells
Online Access:	https://doi.org/10.1002/cti2.70014
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ADA/CD26 axis increases intra-tumor PD-1+CD28+CD8+ T-cell fitness and affects NSCLC prognosis and response to ICB
by: Ornella Franzese, et al.
Published: (2024-12-01)

Upregulation of CD244 promotes CD8+ T cell exhaustion in patients with alveolar echinococcosis and a murine model
by: Maolin Wang, et al.
Published: (2024-11-01)

Ubiquitination of CD47 Regulates Innate Anti‐Tumor Immune Response
by: Qian Gou, et al.
Published: (2025-02-01)

CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy
by: Coralie Schoumacher, et al.
Published: (2024-12-01)

Systematic exploration of the molecular characteristics of CD8+ T cells to predict the response to immunotherapy and the prognosis of patients with colon adenocarcinoma
by: Xin Shen, et al.
Published: (2024-12-01)

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma
by: Aiping Lin, et al.
Published: (2024-12-01)

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma
by: Jian‐Hua Wang, et al.
Published: (2019-03-01)

The role of CD47 in immune escape of colon cancer and its correlation with heterogeneity of tumor immune microenvironment
by: Qiu-Si Tian, et al.
Published: (2024-12-01)

Activin A promoted the anti‐tumor effect of ActRIIA high CD8+ T cells in mouse hepatoma
by: Liangchang Hu, et al.
Published: (2025-01-01)

Exhaustion of CD8pos central memory regulatory T cell differentiation is involved in renal allograft rejection
by: Florian Kälble, et al.
Published: (2025-01-01)

COVID-19 Vaccination and Transient Increase in CD4/CD8 Cell Counts in People with HIV: Evidence from China
by: Yanyan Li, et al.
Published: (2024-12-01)

Expression of membrane-bound β-Klotho on peripheral blood CD4+ and CD8+ T lymphocytes of healthy subjects
by: Yana Todorova, et al.
Published: (2023-03-01)

NRF-1 transcription factor regulates expression of an innate immunity checkpoint, CD47, during melanomagenesis
by: Kuldeep Makwana, et al.
Published: (2024-12-01)

Immunogenic clearance combined with PD-1 blockade elicits antitumor effect by promoting the recruitment and expansion of the effector memory-like CD8+ T cell
by: Seong A Kim, et al.
Published: (2025-01-01)

The Prognostic Significance of CD47, CD68, and CD163 Expression Levels and Their Relationship with MLR and MAR in Locally Advanced and Oligometastatic Nasopharyngeal Carcinoma
by: Asim Armagan Aydin, et al.
Published: (2024-11-01)

CD155 promotes the progression of colorectal cancer by restraining CD8+ T cells via the PI3K/AKT/NF-κB pathway
by: Rongpu Liang, et al.
Published: (2025-02-01)

CD47 in Osteosarcoma: Correlation with Metastasis and Macrophage-Mediated Phagocytosis
by: Yunmi Ko, et al.
Published: (2024-11-01)

Nanoalbumin–prodrug conjugates prepared via a thiolation‐and‐conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T‐cell infiltration
by: Long Chen, et al.
Published: (2023-01-01)

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01)

CD161+CD127+CD8+ T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus
by: Jingjing Qu, et al.
Published: (2024-12-01)

Overexpression of ST8Sia1 inhibits tumor progression by TGF-β1 signaling in rectal adenocarcinoma and promotes the tumoricidal effects of CD8+ T cells by granzyme B and perforin
by: Chang Zhang, et al.
Published: (2025-12-01)

Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5: a case report and literature review
by: Qiu Zhao, et al.
Published: (2024-11-01)

The persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function
by: Vanesa Garrido-Rodríguez, et al.
Published: (2024-12-01)

Bioengineer mesenchymal stem cell for treatment of glioma by IL‐12 mediated microenvironment reprogramming and nCD47‐SLAMF7 mediated phagocytosis regulation of macrophages
by: Man Li, et al.
Published: (2024-12-01)

Intrahepatic CD161hiCD8+T Cell Recruitment Has a Pathogenetic Potential in Chronic HBV Infection
by: Jianfei Li, et al.
Published: (2025-01-01)

RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
by: Xiaobing Duan, et al.
Published: (2024-09-01)

Quantification of heterogeneity in human CD8+ T cell responses to vaccine antigens: an HLA-guided perspective
by: Duane C. Harris, et al.
Published: (2024-11-01)

Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer
by: Ramazan Oguz Yüceer, et al.
Published: (2025-01-01)

Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression
by: Oanh T. P. Nguyen, et al.
Published: (2024-12-01)

Blocking ANGPTL3 and CD47 impact on atherosclerosis-correspondence
by: Han-Yong Hou, et al.
Published: (2025-02-01)

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
by: Vishnu Vijay Vijayan, et al.
Published: (2024-12-01)

Analysis of frequency changes in CD8+ regulatory T cell subsets in peripheral blood of individuals with type 1 diabetes
by: Shu Chen, et al.
Published: (2024-12-01)

AFP shields hepatocellular carcinoma from macrophage phagocytosis by regulating HuR-mediated CD47 translocation in cellular membrane
by: Yinglian Pan, et al.
Published: (2025-02-01)

LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8+ T cells for improving anti-PD-1 antibody therapy
by: Jiqi Shan, et al.
Published: (2024-12-01)

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy
by: Chunmei Yang, et al.
Published: (2024-11-01)

CD8+ T cell exhaustion in the tumor microenvironment of breast cancer
by: Hanghang Xie, et al.
Published: (2024-12-01)

Facilitating cholangiocarcinoma inhibition by targeting CD47
by: Kulthida Vaeteewoottacharn, et al.
Published: (2024-12-01)

Exosomes: Key Messengers Mediating the Interaction Between Tumor Cells and CD8+ T Cells in the Tumor Microenvironment
by: Li Y, et al.
Published: (2025-01-01)

Mature tertiary lymphoid structure associated CD103+ CD8+ Trm cells determined improved anti-tumor immune in breast cancer
by: Qin Fang, et al.
Published: (2025-01-01)

肝星状细胞通过诱导产生CD8+CD28-T淋巴细胞抑制T细胞增殖
Published: (2016-01-01)